


"Express Mail" Label No. EV 291377041 US

Date of Deposit August 23, 2004

PATENT  
Attorney Docket No.: 019282-000110US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:



Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: \_\_\_\_\_

Tara N. Damhoff

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

William J. Dower, et al.

Application No.: 09/661,927

Filed: September 14, 2000

For: SUBSTRATES AND SCREENING  
METHODS FOR TRANSPORT  
PROTEINS

Customer No: 20350

Confirmation No: 1158

Examiner: Epperson, Jon D.

Art Unit: 1639

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98**

**Mail Stop RCE**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Scott Ausenhus", written over the typed name.

Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb  
60286835 v1



PTO/SB/08A (08-03)

Substitute for form 1449 PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/661,927
		Filing Date	September 14, 2000
		First Named Inventor	Barrett, Ronald W.
		Art Unit	1639
		Examiner Name	Epperson, Jon D.
Sheet 1	of 2	Attorney Docket Number 019282-000110US	


U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	A1	US-5,236,902	08-17-1993	Paterson et al.	
	A2				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	PCT	WO 98/38490	A1	09-03-1998			<input type="checkbox"/>
	B2							<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60286835 v1



Substitute for Form 1449B/P <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/661,927		
		Filing Date	September 14, 2000		
		First Named Inventor	Barrett, Ronald W.		
		Art Unit	1639		
		Examiner Name	Epperson, Jon D.		
Sheet	2	of	2	Attorney Docket Number	019282-000110US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	WILTON, J. et al. "Fluorescent Choleretic and Cholestatic Bile Salts Take Different Paths across the Hepatocyte: Transcytosis of Glycolithocholate Leads to and Extensive Redistribution of Annexin II" J. Cell Biology, October 1994, pp. 401-410, Vol. 127, No. 2.	
	C2	SWAAN, PETER et al. "Use of the intestinal and hepatic bile acid transporters for drug delivery" Advanced Drug Delivery Reviews, 1996, pp. 59-82, Vol. 20; Elsevier Science B.V.	
	C3	STEFFANSEN, BENTE et al. "Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption" European Journal of Pharmaceutical Sciences, 2004, pp. 3-16, Vol 21.	
	C4	YANG, CHUN et al. "Prodrug based optimal drug delivery via membrane transporter/receptor" Exp. Opin. Biol. Ther., 2001, pp. 159-175, Vol. 1, No. 2.	
	C5	HAGENBUCH, B. et al. "The superfamily of organic anion transporting polypeptides" Biochimica et Biophysica Acta, 2003, pp. 1-18, Vol. 1609.	
	C6	KIM, R. B. "Organic anion-transporting polypeptide (OATP) transporter family and drug disposition" European Journal of Clinical Investigation, 2003, pp. 1-5, Vol. 33, Suppl. 2.	
	C7	VAN MONTFOORT, J.E., et al. "Drug Uptake Systems in Liver and Kidney" Current Drug Metabolism, 2003, pp. 185-211, Vol. 4.	
	C8	UCHINO, HIROSHI, et al. "Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition" Molecular Pharmacology, 2002, pp. 729-737, Vol. 61, No. 4.	
	C9	TAMAI, IKUMI et al. "Participation of a Proton-Cotransporter, MCT1, in the Intestinal Transport of Monocarboxylic Acids" Biochemical and Biophysical Research Communications, September 14, 1995, pp. 482-489, Vol. 214, No. 2.	
	C10		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.